TABLE 1.
Results for the baseline and current scenarios and benefits to the United States of increasing hepatitis B immunization in the top 10 countries over the period 2000–2070.
| Immigrants w/CHB | Costs ($ Millions) | QALYs (millions) | CC | DC | HCC | HBV deaths | |
|---|---|---|---|---|---|---|---|
| Totals | |||||||
| Baseline | 1,773,057 | 6,831,190 | 1054.62 | 131,765 | 36,762 | 121,430 | 184,761 |
| Current | 1,304,371 | 6,826,965 | 1054.98 | 109,706 | 29,345 | 97,024 | 149,179 |
| WHO | 1,287,610 | 6,826,822 | 1054.99 | 109,199 | 29,134 | 96,315 | 148,190 |
| Comparative benefits | |||||||
| Current vs. Baseline | −468,686 | −4225 | 0.36 | −22,059 | −7417 | −24,406 | −35,582 |
| WHO vs. Baseline | −485,448 | −4368 | 0.37 | −22,566 | −7628 | −25,115 | −36,571 |
| WHO vs. Current | −16,762 | −143 | 0.01 | −507 | −211 | −709 | −989 |
Note: ‘top 10 countries’ refers to China, Vietnam, the Philippines, India, the Dominican Republic, Taiwan, South Korea, Mexico, Nigeria and Haiti. Abbreviations: CC, Compensated Cirrhosis; DC, Decompensated Cirrhosis; HBV, Hepatitis B; HCC, Hepatocellular Carcinoma; QALYs, Quality-Adjusted Life Years.